{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T05:38:01Z","timestamp":1794980281061,"version":"4.9.1"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:00:00Z","timestamp":1763942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:00:00Z","timestamp":1763942400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82400944"],"award-info":[{"award-number":["82400944"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82470907"],"award-info":[{"award-number":["82470907"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China,China","doi-asserted-by":"crossref","award":["82270880"],"award-info":[{"award-number":["82270880"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetol Metab Syndr"],"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Metabolic dysfunction-associated steatohepatitis (MASH) is a progressive liver disease associated with significant morbidity and mortality, yet management options remain limited. Although glucagon-like peptide-1 receptor agonists such as semaglutide have shown benefits in metabolic health, their efficacy and safety in patients with MASH require further elucidation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We systematically searched PubMed, Embase, the Cochrane Library, and ClinicalTrials.gov for randomized controlled trials (RCTs) evaluating semaglutide in patients with MASH from inception through August 23, 2025. This meta-analysis was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 22 RCTs involving 32,013 patients were included. Semaglutide significantly improved MASH Resolution (RR\u2009=\u20091.98, 95%CI: 1.57 to 2.50) but did not yield significant improvement in Fibrosis Regression (RR\u2009=\u20091.18, 95%CI: 0.74 to 1.88). Semaglutide also reduced Liver Steatosis (WMD = -11.30%, 95%CI: -18.70 to -3.91) and the Enhanced Liver Fibrosis (ELF) score (WMD = -0.49, 95%CI: -0.70 to -0.29). Significant reductions were observed in liver enzymes, including alanine aminotransferase (ALT; WMD = -5.55 U\/L, 95%CI: -9.21 to -1.89) and aspartate aminotransferase (AST; WMD = -3.85 U\/L, 95%CI: -7.67 to -0.03). Additionally, semaglutide improved weight management, glycemic and lipid parameters, and reduced all-cause mortality (RR\u2009=\u20090.82, 95%CI: 0.74 to 0.91) and cardiovascular risk (RR\u2009=\u20090.83, 95%CI: 0.75 to 0.92). Subgroup analyses revealed the greatest benefits in patients receiving higher doses (\u2265 2.0\u00a0mg weekly) and longer intervention durations (\u226512 months).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Semaglutide represents a promising pharmacotherapeutic option for MASH, demonstrating significant improvements in histologic resolution, liver injury biomarkers, and metabolic parameters, particularly at higher doses and longer intervention durations, though its effect on fibrosis regression remains limited.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13098-025-01995-z","type":"journal-article","created":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T10:44:20Z","timestamp":1763981060000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["The impact of semaglutide on liver outcomes in patients with or at risk of MASH: a dose and duration response meta-analysis of randomized trials"],"prefix":"10.1186","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-2829-945X","authenticated-orcid":false,"given":"Ranran","family":"Kan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaming","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danpei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuefeng","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,24]]},"reference":[{"key":"1995_CR1","doi-asserted-by":"publisher","unstructured":"Iruzubieta P, Santos-Laso A, Arias-Loste MT, Calleja JL, Crespo J. Evaluation of metabolic dysfunction-Associated steatotic liver disease (MASLD) terminology in different clinical settings. J Hepatol2024; 80(3):e121\u2013e123. https:\/\/doi.org\/10.1016\/j.jhep.2023.10.026.","DOI":"10.1016\/j.jhep.2023.10.026"},{"key":"1995_CR2","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","volume":"78","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, et al. A multisociety delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78:1966\u201386.","journal-title":"Hepatology"},{"key":"1995_CR3","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1002\/hep.32542","volume":"77","author":"PA Shah","year":"2023","unstructured":"Shah PA, Patil R, Harrison SA. Nafld-related hepatocellular carcinoma: the growing challenge. Hepatology. 2023;77:323\u201338.","journal-title":"Hepatology"},{"key":"1995_CR4","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","volume":"73","author":"M Eslam","year":"2020","unstructured":"Eslam M, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73:202\u20139.","journal-title":"J Hepatol"},{"key":"1995_CR5","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1055\/a-0784-8827","volume":"57","author":"E Roeb","year":"2019","unstructured":"Roeb E, Geier A. Nonalcoholic steatohepatitis (NASH) - current treatment recommendations and future developments. Z Gastroenterol. 2019;57:508\u201317.","journal-title":"Z Gastroenterol"},{"key":"1995_CR6","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1053\/j.gastro.2020.05.046","volume":"165","author":"V Ratziu","year":"2023","unstructured":"Ratziu V, Friedman SL. Why do so many nonalcoholic steatohepatitis trials fail? Gastroenterology. 2023;165:5\u201310.","journal-title":"Gastroenterology"},{"key":"1995_CR7","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1111\/imj.16126","volume":"53","author":"B Stretton","year":"2023","unstructured":"Stretton B, et al. Weight loss with subcutaneous semaglutide versus other glucagon-like peptide 1 receptor agonists in type 2 diabetes: a systematic review. Intern Med J. 2023;53:1311\u201320.","journal-title":"Intern Med J"},{"key":"1995_CR8","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","volume":"387","author":"MJ Armstrong","year":"2016","unstructured":"Armstrong MJ, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet. 2016;387:679\u201390.","journal-title":"Lancet"},{"key":"1995_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-01663-y","volume":"11","author":"S Ghosal","year":"2021","unstructured":"Ghosal S, Datta D, Sinha B. A meta-analysis of the effects of glucagon-like-peptide 1 receptor agonist (GLP1-RA) in nonalcoholic fatty liver disease (NAFLD) with type 2 diabetes (T2D). Sci Rep. 2021;11:22063.","journal-title":"Sci Rep"},{"key":"1995_CR10","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1001\/jama.2019.2941","volume":"321","author":"IB Hirsch","year":"2019","unstructured":"Hirsch IB. The future of the GLP-1 receptor agonists. JAMA. 2019;321:1457\u20138.","journal-title":"JAMA"},{"key":"1995_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102181","volume":"64","author":"I Caruso","year":"2023","unstructured":"Caruso I, et al. Glucometabolic outcomes of GLP-1 receptor agonist-based therapies in patients with type 2 diabetes: a systematic review and network meta-analysis. EClinicalMedicine. 2023;64:102181.","journal-title":"EClinicalMedicine"},{"key":"1995_CR12","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1111\/apt.15316","volume":"50","author":"P Newsome","year":"2019","unstructured":"Newsome P, et al. Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and\/or obesity. Aliment Pharmacol Ther. 2019;50:193\u2013203.","journal-title":"Aliment Pharmacol Ther"},{"key":"1995_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.1046130","volume":"13","author":"S Niu","year":"2022","unstructured":"Niu S, et al. Semaglutide ameliorates metabolism and hepatic outcomes in an NAFLD mouse model. Front Endocrinol (Lausanne). 2022;13:1046130.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1995_CR14","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","volume":"71","author":"ZM Younossi","year":"2019","unstructured":"Younossi ZM, et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis. J Hepatol. 2019;71:793\u2013801.","journal-title":"J Hepatol"},{"key":"1995_CR15","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b2535","volume":"339","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535\u20132535.","journal-title":"BMJ"},{"key":"1995_CR16","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.70581","volume":"14","author":"A Ramandi","year":"2025","unstructured":"Ramandi A, et al. The association between serum gamma-glutamyl transferase and gastrointestinal cancer risk: a systematic review and meta-analysis. Cancer Med. 2025;14:e70581.","journal-title":"Cancer Med"},{"key":"1995_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.03.016","author":"F He","year":"2023","unstructured":"He F, et al. ATF4 suppresses hepatocarcinogenesis by inducing SLC7A11 (xCT) to block stress-related ferroptosis. J Hepatol. 2023;79(2):362\u2013377. https:\/\/doi.org\/10.1016\/j.jhep.2023.03.016.","journal-title":"J Hepatol"},{"key":"1995_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102292","author":"JH Moon","year":"2023","unstructured":"Moon JH, Jeong S, Jang H, Koo BK, Kim W. Metabolic dysfunction-associated steatotic liver disease increases the risk of incident cardiovascular disease: a nationwide cohort study. eClinicalMedicine. 2023. https:\/\/doi.org\/10.1016\/j.eclinm.2023.102292.","journal-title":"eClinicalMedicine"},{"key":"1995_CR19","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1002\/hep.20701","volume":"41","author":"DE Kleiner","year":"2005","unstructured":"Kleiner DE, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313\u201321.","journal-title":"Hepatology"},{"key":"1995_CR20","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1148\/radiol.2021204288","volume":"301","author":"J Starekova","year":"2021","unstructured":"Starekova J, Hernando D, Pickhardt PJ, Reeder SB. Quantification of liver fat content with CT and MRI: state of the art. Radiology. 2021;301:250\u201362.","journal-title":"Radiology"},{"key":"1995_CR21","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JPT Higgins","year":"2011","unstructured":"Higgins JPT, et al. The cochrane collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928\u20135928.","journal-title":"BMJ"},{"issue":"7650","key":"1995_CR22","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GHOA Guyatt","year":"2008","unstructured":"Guyatt GHOA, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Sch\u00fcnemann HJ, GRADE Working Group. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924\u20136.","journal-title":"BMJ"},{"issue":"7414","key":"1995_CR23","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JPTS Higgins","year":"2003","unstructured":"Higgins JPTS, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557\u201360.","journal-title":"BMJ"},{"key":"1995_CR24","doi-asserted-by":"publisher","first-page":"258","DOI":"10.2337\/dc17-0417","volume":"41","author":"AJ Ahmann","year":"2018","unstructured":"Ahmann AJ, et al. Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type 2 diabetes (SUSTAIN 3): a 56-week, open-label, randomized clinical trial. Diabetes Care. 2018;41:258\u201366.","journal-title":"Diabetes Care"},{"key":"1995_CR25","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.jhep.2022.04.003","volume":"77","author":"N Alkhouri","year":"2022","unstructured":"Alkhouri N, et al. Safety and efficacy of combination therapy with semaglutide, Cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: a randomised, open-label phase II trial. J Hepatol. 2022;77:607\u201318.","journal-title":"J Hepatol"},{"key":"1995_CR26","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1001\/jama.2017.14752","volume":"318","author":"M Davies","year":"2017","unstructured":"Davies M, Pieber TR, Hartoft-Nielsen ML, Hansen OKH, Jabbour S, Rosenstock J. Effect of oral semaglutide compared with placebo and subcutaneous semaglutide on glycemic control in patients with type 2 diabetes: a randomized clinical trial. JAMA. 2017;318:1460\u201370.","journal-title":"JAMA"},{"key":"1995_CR27","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/S0140-6736(21)00213-0","volume":"397","author":"M Davies","year":"2021","unstructured":"Davies M, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021;397:971\u201384.","journal-title":"Lancet"},{"key":"1995_CR28","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1111\/apt.16608","volume":"54","author":"A Flint","year":"2021","unstructured":"Flint A, et al. Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non-alcoholic fatty liver disease assessed by magnetic resonance imaging. Aliment Pharmacol Ther. 2021;54:1150\u201361.","journal-title":"Aliment Pharmacol Ther"},{"key":"1995_CR29","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1056\/NEJMoa2107519","volume":"385","author":"JP Frias","year":"2021","unstructured":"Frias JP, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385:503\u201315.","journal-title":"N Engl J Med"},{"key":"1995_CR30","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1038\/s41591-022-02026-4","volume":"28","author":"WT Garvey","year":"2022","unstructured":"Garvey WT, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med. 2022;28:2083\u201391.","journal-title":"Nat Med"},{"key":"1995_CR31","doi-asserted-by":"publisher","first-page":"3632","DOI":"10.1111\/dom.15258","volume":"25","author":"T Kimura","year":"2023","unstructured":"Kimura T, et al. Comparison of clinical efficacy and safety of weekly glucagon-like peptide-1 receptor agonists dulaglutide and semaglutide in Japanese patients with type 2 diabetes: randomized, parallel-group, multicentre, open-label trial (COMING study). Diabetes Obes Metab. 2023;25:3632\u201347.","journal-title":"Diabetes Obes Metab"},{"key":"1995_CR32","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","volume":"392","author":"AJ Sanyal","year":"2025","unstructured":"Sanyal AJ, et al. Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis. N Engl J Med. 2025;392:2089\u201399.","journal-title":"N Engl J Med"},{"key":"1995_CR33","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/S0140-6736(23)01185-6","volume":"402","author":"FK Knop","year":"2023","unstructured":"Knop FK, et al. Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;402:705\u201319.","journal-title":"Lancet"},{"key":"1995_CR34","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2307563","author":"AM Lincoff","year":"2023","unstructured":"Lincoff AM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221\u20132232. https:\/\/doi.org\/10.1056\/NEJMoa2307563.","journal-title":"N Engl J Med"},{"key":"1995_CR35","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/S2468-1253(23)00068-7","volume":"8","author":"R Loomba","year":"2023","unstructured":"Loomba R, et al. Semaglutide 2\u00b74\u00a0mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial. Lancet Gastroenterol Hepatol. 2023;8:511\u201322.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"1995_CR36","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375:1834\u201344.","journal-title":"N Engl J Med"},{"key":"1995_CR37","doi-asserted-by":"publisher","first-page":"231","DOI":"10.2337\/dc15-0165","volume":"39","author":"MA Nauck","year":"2016","unstructured":"Nauck MA, et al. A phase 2, randomized, dose-finding study of the novel once-weekly human GLP-1 analog, semaglutide, compared with placebo and open-label liraglutide in patients with type 2 diabetes. Diabetes Care. 2016;39:231\u201341.","journal-title":"Diabetes Care"},{"key":"1995_CR38","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/S0140-6736(18)31773-2","volume":"392","author":"PM O\u2019Neil","year":"2018","unstructured":"O\u2019Neil PM, et al. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. Lancet. 2018;392:637\u201349.","journal-title":"Lancet"},{"key":"1995_CR39","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S0140-6736(19)31271-1","volume":"394","author":"R Pratley","year":"2019","unstructured":"Pratley R, et al. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial. Lancet. 2019;394:39\u201350.","journal-title":"Lancet"},{"key":"1995_CR40","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1016\/j.jhep.2023.05.013","volume":"79","author":"M Romero-Gomez","year":"2023","unstructured":"Romero-Gomez M, et al. A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of Efinopegdutide in patients with non-alcoholic fatty liver disease. J Hepatol. 2023;79:888\u201397.","journal-title":"J Hepatol"},{"key":"1995_CR41","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1001\/jama.2021.3224","volume":"325","author":"D Rubino","year":"2021","unstructured":"Rubino D, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA. 2021;325:1414\u201325.","journal-title":"JAMA"},{"key":"1995_CR42","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1111\/dom.13082","volume":"20","author":"Y Seino","year":"2018","unstructured":"Seino Y, et al. Safety and efficacy of semaglutide once weekly vs sitagliptin once daily, both as monotherapy in Japanese people with type 2 diabetes. Diabetes Obes Metab. 2018;20:378\u201388.","journal-title":"Diabetes Obes Metab"},{"key":"1995_CR43","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1001\/jama.2021.1831","volume":"325","author":"TA Wadden","year":"2021","unstructured":"Wadden TA, et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial. JAMA. 2021;325:1403\u201313.","journal-title":"JAMA"},{"key":"1995_CR44","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","volume":"384","author":"JPH Wilding","year":"2021","unstructured":"Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384:989\u20131002.","journal-title":"N Engl J Med"},{"key":"1995_CR45","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","volume":"384","author":"PN Newsome","year":"2021","unstructured":"Newsome PN, et al. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med. 2021;384:1113\u201324.","journal-title":"N Engl J Med"},{"key":"1995_CR46","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1111\/apt.16794","volume":"55","author":"ASt Barritt","year":"2022","unstructured":"Barritt ASt, Marshman E, Noureddin M. Review article: role of glucagon-like peptide-1 receptor agonists in non-alcoholic steatohepatitis, obesity and diabetes-what hepatologists need to know. Aliment Pharmacol Ther. 2022;55:944\u201359.","journal-title":"Aliment Pharmacol Ther"},{"key":"1995_CR47","doi-asserted-by":"crossref","unstructured":"Souza M, Al-Sharif L, Antunes VLJ, Huang DQ, Loomba R. Comparison of Pharmacological therapies in metabolic dysfunction-associated steatohepatitis for fibrosis regression and MASH resolution: systematic review and network meta-analysis. Hepatology, (2025); (in press).","DOI":"10.1097\/HEP.0000000000001254"},{"key":"1995_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-022-01119-3","author":"X Xu","year":"2022","unstructured":"Xu X, et al. Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver\/steatohepatitis (NAFL\/NASH). Signal Transduct Target Ther. 2022;7(1):287. https:\/\/doi.org\/10.1038\/s41392-022-01119-3.","journal-title":"Signal Transduct Target Ther"},{"key":"1995_CR49","doi-asserted-by":"publisher","first-page":"77","DOI":"10.3350\/cmh.2022.0237","volume":"29","author":"KC Lee","year":"2023","unstructured":"Lee KC, Wu PS, Lin HC. Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis. Clin Mol Hepatol. 2023;29:77\u201398.","journal-title":"Clin Mol Hepatol"},{"key":"1995_CR50","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1038\/s41591-023-02242-6","volume":"29","author":"SA Harrison","year":"2023","unstructured":"Harrison SA, Allen AM, Dubourg J, Noureddin M, Alkhouri N. Challenges and opportunities in NASH drug development. Nat Med. 2023;29:562\u201373.","journal-title":"Nat Med"},{"key":"1995_CR51","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1111\/dom.16065","volume":"27","author":"MJ Armstrong","year":"2025","unstructured":"Armstrong MJ, Okanoue T, Sundby Palle M, Sejling AS, Tawfik M, Roden M. Similar weight loss with semaglutide regardless of diabetes and cardiometabolic risk parameters in individuals with metabolic dysfunction-associated steatotic liver disease: post hoc analysis of three randomised controlled trials. Diabetes Obes Metab. 2025;27:710\u20138.","journal-title":"Diabetes Obes Metab"},{"key":"1995_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.dsx.2022.102539","volume":"16","author":"D Dutta","year":"2022","unstructured":"Dutta D, Kumar M, Shivaprasad KS, Kumar A, Sharma M. Impact of semaglutide on biochemical and radiologic measures of metabolic-dysfunction associated fatty liver disease across the spectrum of glycaemia: a meta-analysis. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2022;16:102539.","journal-title":"Diabetes & Metabolic Syndrome: Clinical Research & Reviews"},{"key":"1995_CR53","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1515\/jpem-2019-0403","volume":"33","author":"RZ Mohamed","year":"2020","unstructured":"Mohamed RZ, Jalaludin MY, Anuar Zaini A. Predictors of non-alcoholic fatty liver disease (NAFLD) among children with obesity. J Pediatr Endocrinol Metab. 2020;33:247\u201353.","journal-title":"J Pediatr Endocrinol Metab"}],"container-title":["Diabetology &amp; Metabolic Syndrome"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13098-025-01995-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13098-025-01995-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13098-025-01995-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T18:13:42Z","timestamp":1764180822000},"score":1,"resource":{"primary":{"URL":"https:\/\/dmsjournal.biomedcentral.com\/articles\/10.1186\/s13098-025-01995-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,24]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1995"],"URL":"https:\/\/doi.org\/10.1186\/s13098-025-01995-z","relation":{},"ISSN":["1758-5996"],"issn-type":[{"value":"1758-5996","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,24]]},"assertion":[{"value":"17 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"439"}}